Additionally, the determination of TTC17 based on molecular subtypes indicated that human epidermal growth factor receptor 2 (HER2)-positive and triple-negative BC, representing the intractable subpopulations, had even lower levels of TTC17 expression than luminal subsets with lower aggressiveness (Fig. 2i). This evidence concerns the gene ERBB2 and breast cancer.